

Innovative therapy, monoclonal antibodies and beyond - 7th Edition

Friday, 27 January 2017

Rationale

The 7th "Innovative therapy, monoclonal antibodies and beyond" Conference will collect leading international experts in the field of immuno-oncology and cancer cell signaling to understand the potential, opportunities and challenges of the immunotherapy and targeted therapies. The key role of the immune system in cancer has been recognized for a long time. Our understanding of the co-evolution of cancer and the immune system has significantly improved, with significant results in clinic. Indeed, the increasing knowledge of the molecular mechanisms responsible for neoplastic transformation, the biology of cancer cells, and the immunological mechanisms regulating tumor-host interaction, allowed us to identify and apply more effective anti-cancer biological and immunological treatments. To date, the immuno-biotherapy is a continuously evolving treatment modality and it is currently integrated into the treatment algorithms of several different tumor types. Furthermore, elucidating resistance mechanisms and exploiting cancer vulnerabilities to therapeutics will ultimately improve cancer therapy and patient care. This conference explores topics that will appeal to clinicians, as well as, basic, translational, and clinical scientists ranging from academics to industry. As in the past, the meeting will provide a highly interactive forum in which leading experts will discuss clinical and pre-clinical data, providing the audience with a broad overview of the most recent achievements in cancer biologic and immunologic therapy. Finally, several data supporting the combination of immunotherapies and standard treatments open an intriguing challenge, but also a real opportunity for the future therapeutic approaches.

PRELIMINARY PROGRAM

Welcome Coffee

- 08.00 – 09.00 Registration
09.00 – 09.10 Welcome remarks of Authorities
09.10 – 09.20 Introduction
M. Di Nicola (Milan, Italy)

I SESSION: Preclinical assays and novel biotargets

Chairmen: **M. Di Nicola (Milan, Italy)**

- 09.20-09.50 Mismatch repair and clonal neoantigens
L.A. Diaz (Baltimore, USA)
- 09.50-10.20 The role of microbiota and immunotherapy
M. Colombo (Milan, Italy)
- 10.20-10.50 Commensal bacteria drive extramucosal cancer progression by inducing interleukin-17-producing cells
M. Bellone (Milan, Italy)

NADIREX INTERNATIONAL Srl

10.50-11.20 Immunogenic cell death-inducing chemotherapies trigger PD-L1 dependent adaptive immune resistance to cancer

L. Apetoh (Dijon, France)

11.20-11.50 A Complement to cancer stromal microenvironment

C. Tripodo (Palermo, Italy)

11.50-12.10 General discussion

Keynote Lecture

12.10-12.55 HLA antigens modulation and response to immunocheck-point inhibitor immunotherapy
S. Ferrone (Boston, USA)

12.55-14.25 Buffet Lunch

II SESSION: Monoclonal antibodies, cell therapies and targeted molecules

Chairmen: **M. Del Vecchio (Milan, Italy), A. Anichini (Milan, Italy)**

14.25-14.55 New insights on CAR-T cells in solid tumors

G. Dotti, (Chapel Hill, USA)

14.55-15.25 Oncolytic virus vaccination

J. Hiscott (Rome, Italy)

15.25-15.55 Combination immunotherapy: novel phase I studies

M. Di Nicola (Milan, Italy)

15.55-16.25 Immunotherapy and targeted therapy in melanoma: combination strategy

M. Del Vecchio (Milan, Italy)

16.25-17.00 Discussion

17.00 Conclusions

M. Del Vecchio (Milan, Italy)